Jared Gollob, Chief Medical Officer at Kymera Therapeutics, Inc. (KYMR), sold 21,016 shares at $87.75 ($1.8M) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Seasonal sale ($1.8M) by Chief Medical Officer — this insider has traded KYMR in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.75 | 1,510 | $133K | 7.2% |
| 2 | $87.75 | 1,510 | $133K | 7.2% |
| 3 | $88.50 | 1,055 | $93K | 5.1% |
| 4 | $88.50 | 1,055 | $93K | 5.1% |
| 5 | $89.66 | 3,048 | $273K | 14.9% |
| 6 | $89.66 | 3,048 |
| $273K |
| 14.9% |
| 7 | $84.00 | 492 | $41K | 2.3% |
| 8 | $84.00 | 492 | $41K | 2.3% |
| 9 | $85.04 | 2,519 | $214K | 11.7% |
| 10 | $85.04 | 2,519 | $214K | 11.7% |
| 11 | $85.78 | 1,437 | $123K | 6.7% |
| 12 | $85.78 | 1,437 | $123K | 6.7% |
| 13 | $86.62 | 447 | $39K | 2.1% |
| 14 | $86.62 | 447 | $39K | 2.1% |
| Total | $87.24 avg | 21,016 | $1.8M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $187K | — | Filing → |
| KYMR | SELL | 2025-03-03 | $317K | — | Filing → |
| KYMR | SELL | 2024-07-16 | $3.6M | — | Filing → |